Business
The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults
The olanzapine long-acting injectable (TEV-’749) is designed to deliver the efficacy of olanzapine in a subcutaneous formulation1 administered every four weeks.If approved, TEV-‘749 could help fill a significant unmet need in available schizophrenia treatment options by addressing the lack of a viable long-acting olanzapine formulation.Teva is committed to advancing this innovative treatment option, strengthening its scientific leadership in complex neurological conditions as part of its Pivot t
About this update from Teva Pharmaceutical Industries Limited
[{"type":"image","alt":"Teva Pharmaceutical Industries Ltd","displaySize":"","headline":null,"caption":"Teva Pharmaceutical Industries Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/bfbffad044ba3112cbe08e7be13bb2e7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/RVm0LbdD5btgTSMRlhCNHQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MQ--/https://media.zenfs.com/en/globenewswire.com/bfbffad044ba3112cbe08e7be13bb2e7","width":300,"height":108},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/RVm0LbdD5btgTSMRlhCNHQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MQ--/https://media.zenfs.com/en/globenewswire.com/bfbffad044ba3112cbe08e7be13bb2e7","width":300,"height":108}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"The olanzapine long-acting injectable (TEV-’749) is designed to deliver the efficacy of olanzapine in a subcutaneous formulation1 administered every four weeks.","length":160,"tagName":"p"}]},{"val":[{"type":"text","content":"If approved, TEV-‘749 could help fill a significant unmet need in available schizophrenia treatment options by addressing the lack of a viable long-acting olanzapine formulation.","length":178,"tagName":"p"}]},{"val":[{"type":"text","content":"Teva is committed to advancing this innovative treatment option, strengthening its scientific leadership in complex neurological conditions as part of its Pivot to Growth strategy.","length":180,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":518,"olType":false},{"type":"text","content":"TEL AVIV, Israel and PARIS, May 21, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and Medincell (Euronext: MEDCL), today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for olanzapine long-acting injectable (TEV-‘749) for the treatment of schizophrenia in adults. TEV-‘749 aims to address treatment adherence in real-world settings and contribute to long-term disease management in people living with schizophrenia.1","length":573,"tagName":"p"},{"type":"text","content":"“Treatment adherence remains a challenge for people living with schizophrenia including those who rely on oral forms of Olanzapine. TEV-‘749, our investigation...